Searched for
SUN PHARMA BUYOUT
Organon gives Sun Pharma scale and reach, but challenge lies in integration, executionSun Pharma has acquired Organon & Co for $11.75 billion. This deal provides Sun Pharma with expanded global scale and commercial reach. It ...
Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
Sun Pharma deal structurally strong, debt the only overhang: Amit KhuranaMarket expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
Taro stake buyout to help operate its dermatology biz profitably amid enhanced competition: Sun PharmaThe company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the out...
Sun Pharma plans in-licensing, buyouts to expand speciality businessSpeciality drugs refer to high cost, high complexity medicines, including biologicals, for the treatment of complex or rare conditions. The...
Current headwinds to help shape M&A contours for Indian pharmaDrugmakers have reported impairments, reduced revenue guidance, or stretched the payback time.
Sun Pharma in race for UK buyout in hospital-initiated & emergency care segmentSun Pharma is eyeing a controlling stake in UK based Bolt Equity Limited which is backed by AAC Capital.
Clean chit to Halol plant, strategic buys key for Sun Pharma's futureSun management, in the post-results earnings call, admitted Ranbaxy's integration is likely to take more time than originally envisaged.
Sun Pharma’s stocks surge after merger with TaroSince 2013, Sun Pharma stock has doubled from below Rs 400 to a level closer to the Rs 1,000 mark – making Dilip Shanghvi, the richest bill...
Not just MNCs, local cash-rich pharma companies also take to deal streetMultinational firms have been usually acquiring Indian drugmakers to expand in the country and leverage their manufacturing facilities.
Sun Pharma drops plan to buy out Taro’s minority shareholdersSun Pharma had acquired majority stake (66%) in the Israeli generic firm Taro Pharma in 2007 for $450 million, but got control of the compa...
Sun Pharma outsmarts peers in terms of shareholders' valueSun has had its fair share of problems but has managed to extricate itself quickly and turn things around.
Taro postpones shareholders meeting on merger with Sun PharmaIsraeli firm Taro Pharmaceutical Industries Ltd said it postponed a meeting of shareholders to consider the company's proposed merger with ...
- Taro Pharmaceuticals' excellent Q4 performance may kill Sun Pharma buyout
Sun Pharma's proposed buyout of Taro Pharmaceuticals might have been "killed" by the Israeli company's exceptional Q4 performance, said med...
- Sun Pharma to buy Taro for $454 mn
Second-largest overseas buyout by an Indian pharma company will give Sun an edge in North America where Israeli generics player records 90%...